Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Cancer Epidemiology and Prevention
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1411096

New model to predict survival in advanced pancreatic ductal adenocarcinoma patients by measuring GGT and LDH levels and monocyte count

Provisionally accepted
Rocío Del Campo-Pedrosa Rocío Del Campo-Pedrosa 1,2*Alfonso Martín-Carnicero Alfonso Martín-Carnicero 3Ana González-Marcos Ana González-Marcos 2Alfredo Martínez Alfredo Martínez 4
  • 1 Encore Lab SL, Logroño, Spain
  • 2 University of La Rioja, Logroño, La Rioja, Spain
  • 3 Hospital San Pedro, Logroño, La Rioja, Spain
  • 4 Centro de Investigación Biomédica de La Rioja, Logroño, La Rioja, Spain

The final, formatted version of the article will be published soon.

    Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a poor survival outcome. Predicting patient survival allows physicians to tailor treatments to specific individuals. Thus, a simple and cost-effective prognosis model is sorely needed. Methods: This retrospective study assesses the prognostic value of blood biomarkers in advanced and metastatic PDAC patients (n=96) from Spain. Cut-off points for hematological parameters were calculated and correlated with overall survival (OS) using Kaplan-Meier, log-rank test, robust Cox proportional hazards and logistic regressions. Results: In univariate analysis, individuals with low levels of GGT, LDH, ALP, leukocyte-, neutrophil- and monocyte counts showed significantly longer survival than patients with higher levels. In multivariate analysis, lower levels of GGT (HR (95%CI), 2.734 (1.223-6.111); p=0.014), LDH (HR (95%CI), 1.876 (1.035-3.400); p=0.038) and monocyte count (HR (95%CI), 1.657 (1.095-2.506); p = 0.017) remained significantly beneficial. In consequence, we propose a prognostic model based on logistic regression (AUC=0.741) of these three biomarkers as a pioneer tool to estimate OS in PDAC. Conclusion: This study has demonstrated that the joint use of GGT (<92.00), LDH (<220.00) and monocyte count (<800) are independent positive prognostic factors in PDAC that can predict one-year survival in a novel prognostic logistic model.

    Keywords: Prognosis model, Prognostic biomarkers, overall survival, Gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH), advanced and metastatic pancreatic cancer, Pancreatic ductal adenocarcinoma (PDAC)

    Received: 02 Apr 2024; Accepted: 23 Sep 2024.

    Copyright: © 2024 Del Campo-Pedrosa, Martín-Carnicero, González-Marcos and Martínez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Rocío Del Campo-Pedrosa, Encore Lab SL, Logroño, Spain

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.